111 filings
Page 5 of 6
8-K
9bqsqx dh9nlham1p
4 Dec 17
Departure of Directors or Certain Officers
12:00am
8-K
cyenr
28 Nov 17
CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic
12:00am
8-K
c8v 6lfi8hzssf7c8zi
7 Nov 17
CytomX Announces Third Quarter 2017 Financial Results and Operational Progress
12:00am
8-K
b69 eipzq1y2tyo4
24 Oct 17
CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to
12:00am
8-K
yblmk1 19jd5miulufs1
3 Oct 17
Amgen and Cytomx Therapeutics Announce
12:00am
8-K
5p9x8c vcgsm2hc
7 Aug 17
CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call
12:00am
8-K
bjlxll3awoqcqwzd
17 Jul 17
Changes in Registrant's Certifying Accountant
12:00am
8-K
oatjmtod8 zf
29 Jun 17
CytomX Achieves Development Milestone in Strategic Oncology Collaboration with AbbVie for CD71-Targeting Probody Drug Conjugate
12:00am
8-K
jkkj blf6qjt9u
28 Jun 17
CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-CX-2009 Trial
12:00am
8-K
8sfuiukl
21 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
6ehwyjgoey6ei91 9fan
15 May 17
Departure of Directors or Certain Officers
12:00am
8-K
g1z sudxzpi
5 May 17
CytomX Announces First Quarter 2017 Financial Results
12:00am
8-K
jb90l8 pdt
30 Mar 17
CytomX Therapeutics Appoints Marion McCourt to Board of Directors
12:00am
8-K
0yis2g5 euo6j0
20 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
tw4myhy0u9h
2 Mar 17
CytomX Announces Full-Year 2016 Financial Results
12:00am
8-K
qk244y
10 Jan 17
Results of Operations and Financial Condition
12:00am
8-K
m5g03tx n1
14 Dec 16
CytomX Announces U.S. FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Study of Anti-PD-L1 Probody Therapeutic, CX-072
12:00am
8-K
xz7dhbmzw
13 Dec 16
CytomX Announces Selection by Bristol-Myers Squibb of First Clinical Candidate Probody From Collaboration
12:00am
8-K
0slq0crnzvyo b1
5 Dec 16
CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration
12:00am
8-K
84zow21b7b6 no0xn
3 Nov 16
CytomX Therapeutics Announces Third Quarter 2016 Financial Results and Provides Pipeline Update
12:00am